Clinical Trial Update: 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of 131I-rituximab for relapsed or refractory marginal Zone B-cell lymphoma; current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone B-cell Lymphoma

Drugs mentioned

• 131I-rituximab

Snippet

Sponsor: Korea Cancer Center Hospital | Conditions: Relapsed or Refractory Marginal Zone B-cell Lymphoma | Phase 2 | Status: UNKNOWN